Supporting Information For

Rhodium(III)-catalyzed C2-selective carbenoid

functionalization and subsequent C7-alkenylation of indoles

Jingjing Shi,^a Yunnan Yan,^{ab} Qiu Li,^a H. Eric Xu*^{ac} and Wei Yi*^a

Fax:+86-21-20231000-1715; e-mail: yiwei.simm@simm.ac.cn, eric.xu@simm.ac.cn;

Table of contents

General methods and materials	2
General procedure for synthesis of the starting materials	2-3
General procedure for C2-alkylation reaction	3
General procedure for C7-alkenylation reaction	3
Procedure for deprotection	4
Characterizations of products 3a-3u and 4-7	5-15
References	15
¹ H and ¹³ C NMR spectra of products 3a-3u and 4-7	16-40

^a VARI/SIMM Center, Center for Structure and Function of Drug Targets, CAS-Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, P.R. China

^b College of Pharmaceutical Sciences, Gannan Medical University, Ganzhou, Jiangxi 341000, P.R. China

^c Laboratory of Structural Sciences, Program on Structural Biology and Drug Discovery, Van Andel Research Institute, Grand Rapids, Michigan 49503, USA

General methods and materials:

 $[Cp*Rh(MeCN)_3](SbF_6)_2$ and $[Cp*RhCl_2]_2$,^{S1} substrate 1-(Pyrimidin-2-yl)-1H-indole^{S2-4} and α -diazotized meldrum's acid^{S5} were synthesized according to published procedures. Other chemicals were purchased from commercial suppliers and were dried and purified when necessary. The water used was re-distillated and ion-free.

¹H and ¹³C NMR spectra were recorded on Varian Mercury-Plus 400 NMR and Varian Mercury-Plus 500 NMR instruments (¹H 400 MHz; ¹³C 100 or 125 MHz) in CDCl₃ or DMSO-*d*₆. Abbreviations for data quoted are s, singlet; brs, broad singlet; d, doublet; t, triplet; dd, doublet of doublets; m, multiplet. High-resolution mass spectra were measured on a agilent TOF-G6230B mass spectrometer. Thin-layer chromatographies were done on pre-coated silica gel 60 F254 plates (Merck). Silica gel 60H (200-300 mesh) manufactured by Qingdao Haiyang Chemical Group Co. (China) was used for general chromatography.

General procedure for synthesis of the starting materials 1: S2-S4



NaH (60% dispersion in mineral oil, 11.0 mmol) was added in portions at 0 $\,^{\circ}$ C to a stirred solution of indoles (10.0 mmol) in dry DMF (25 mL). After stirring for 30 min at 0 $\,^{\circ}$ C, 2-chloropyrimidine (12.0 mmol) was added and then the mixture was stirred at 130 $\,^{\circ}$ C for 24 h. Then, the reaction mixture was cooled to ambient temperature, poured into H₂O (300 mL) and extracted with EtOAc (250 mL). The organic phase was dried over anhydrous Na₂SO₄. After evaporation of the solvents under reduced pressure, the crude product was purified on a silica gel column using EtOAc/petroleum ether (1:10) to get the corresponding product. Characterization of these compounds have been described in the previous report.^{S2-4}

General procedure for synthesis of the starting materials 2:



Meldrum's acid (2.9 g, 20 mmol, 1.0 eq.), triethylamine (3.1 mL, 22 mmol, 1.1 eq.) and 4-acetamidobenzenesulfonyl azide (5.3 g, 22 mmol, 1.1 eq.) were dissolved in acetonitrile (200

mL) at room temperature. After stirring the resulting mixture overnight, the suspension was filtered through a plug of cotton wool and the solvent was removed under reduced pressure. The crude was partitioned between dichloromethane (200 mL) and water (200 mL), and filtered through a plug of cotton wool. The two layers were separated and the aqueous layer was extracted with dichloromethane (200 mL). The combined organic layers were dried over MgSO4, concentrated under reduced pressure and dried under vacuum. Purification by flash column chromatography (silica, pentane/ethyl acetate 8:1) afforded the compound as a colorless solid. Characterization of this compound has been described in the previous report.^{S5}

General procedure for C2-alkylation reaction:



The mixture of $[Cp*Rh(MeCN)_3](SbF_6)_2$ (4.0 mg, 0.005 mmol, 0.05 eq.), substrate **A** (0.12 mmol, 1.2 eq.), **B** (0.10 mmol, 1.0 eq.) and ROH (0.5 mL) were stirred at 80 °C for 15 h under air. The resulting mixture was cooled to room temperature, silica gel column directly to give the desired product.

General procedure for C7-alkenylation reaction:



The mixture of $[Cp*RhCl_2]_2$ (3.0 mg, 0.005 mmol, 0.05 eq.), $Cu(OAc)_2H_2O$ (20mg, 0.10 mmol, 1.0 eq.), substrate **C** (0.10 mmol, 1.0 eq.), methyl acrylate (0.15 mmol, 1.5 eq.) and DMF (0.5 mL) were stirred at 80 °C for 6 h under air. The resulting mixture was cooled to room temperature, diluted with EtOAc (10 mL) and washed brine (10 mL × 2). The organic phase was dried (Na₂SO₄). After evaporation of the solvents under reduced pressure, silica gel column directly to give the desired product.

Procedure for deprotection:



A suspension of **3l** (414 mg, 1 mmol) and NaOEt (340 mg, 5 mmol) in dry DMSO (5 mL) under N_2 was stirred at 80 °C until consumption of the starting material (typically 10 min). It was allowed to reach room temperature, 2N HCl was added, diluted with EtOAc (40 mL) and washed brine. The combined organic phase was dried (Na₂SO₄). After evaporation of the solvents under reduced pressure, the crude product was purified on a silica gel column on a silica gel column to afford the product **7**.

Characterizations of products 3a-3u and 4-7:

Ethyl 2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3a)



This compound was obtained in 89% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.71 (d, *J* = 4.8 Hz, 2H), 8.57 (d, *J* = 8.4 Hz, 1H), 7.57 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.32-7.28 (m, 1H), 7.24-7.20 (m, 1H), 7.08 (t, *J* = 4.8 Hz, 1H), 6.60 (s, 1H), 4.20 (s, 2H), 4.09 (q, *J* = 7.2 Hz, 2H), 1.13 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.3, 157.8, 157.3, 136.4, 133.1, 128.6, 122.9, 121.7, 119.7, 116.1, 114.9, 109.3, 60.2, 36.8, 13.7; HRMS (ESI) calcd for 281.1164 ([M+H]⁺), found 281.1169 ([M+H]⁺).

Ethyl 2-(3-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3b)



This compound was obtained in 85% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.68 (d, *J* = 4.8 Hz, 2H), 8.54 (d, *J* = 8.0 Hz, 1H), 7.55 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.33-7.28 (m, 1H), 7.26-7.23 (m, 1H), 7.04 (t, *J* = 4.8 Hz, 1H), 4.16 (s, 2H), 4.10 (q, *J* = 7.2 Hz, 2H), 2.33 (s, 3H), 1.15 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.8, 158.2, 157.6, 136.0, 130.3, 129.0, 123.5, 121.7, 118.3, 116.1, 115.8, 114.9, 60.5, 34.0, 14.2, 8.9; HRMS (ESI) calcd for 295.1321 ([M+H]⁺), found 295.1327 ([M+H]⁺).

Ethyl 2-(4-methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3c)



This compound was obtained in 91% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.69 (d, J = 4.8 Hz, 2H), 8.15 (d, J = 8.4 Hz, 1H), 7.21 (t, J = 8.0 Hz, 1H), 7.07 (t, J = 4.8 Hz, 1H), 6.72 (d, J = 0.4 Hz, 1H), 6.66 (d, J = 8.0 Hz, 1H), 4.18 (s, 2H), 4.07 (q, J = 7.2 Hz, 2H), 3.95 (s, 3H), 1.11 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.7, 158.3, 157.7, 152.4, 138.1, 131.9, 124.0, 119.3, 116.6, 108.5, 106.5, 102.3, 60.5, 55.3, 37.1, 14.1; HRMS (ESI) calcd for 311.1270 ([M+H]⁺), found 311.1273 ([M+H]⁺).

Ethyl 2-(4-cyano-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3d)



This compound was obtained in 76% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.79 (d, *J* = 8.4 Hz, 1H), 8.75 (d, *J* = 4.8 Hz, 2H), 7.54 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.32 (dd, *J* = 8.4, 1.2 Hz, 1H), 7.18 (t, *J* = 4.8 Hz, 1H), 6.83 (s, 1H), 4.26 (s, 2H), 4.10 (q, *J* = 7.2 Hz, 2H), 1.15 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.1, 158.0, 157.8, 136.6, 130.8, 126.8, 123.1, 120.1, 118.3, 117.6, 107.8, 102.7, 100.0, 60.9, 37.1, 14.2; HRMS (ESI) calcd for 306.1117 ([M+H]⁺), found 306.1126 ([M+H]⁺).

Ethyl 2-(5-fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3e)



This compound was obtained in 92% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.69 (d, J = 4.8 Hz, 2H), 8.54 (q, J = 4.8 Hz, 1H), 7.21 (dd, J = 8.8, 2.8 Hz, 1H), 7.09 (t, J = 4.8 Hz, 1H), 7.01 (dt, J = 4.8 Hz, 1H

9.2, 2.8 Hz, 1H), 6.55 (d, J = 0.8 Hz,1H), 4.18 (s, 2H), 4.10 (q, J = 7.2 Hz, 2H), 1.15 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ: 170.1, 155.5 (d, J = 236.4 Hz), 157.6, 157.3, 134.7, 132.8, 129.3 (d, J = 10.1 Hz), 116.3, 116.1 (d, J = 8.9 Hz), 110.6 (d, J = 24.5 Hz), 109.0 (d, J = 3.9 Hz), 104.8 (d, J = 23.4 Hz), 60.2, 36.8, 13.7; HRMS (ESI) calcd for 299.1070 ([M+H]⁺), found 299.1072 ([M+H]⁺).

Ethyl 2-(5-chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3f)



This compound was obtained in 86% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.70 (d, J = 4.8 Hz, 2H), 8.51 (d, J = 8.8 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.22 (dd, J = 8.8, 2.0 Hz, 1H), 7.10 (t, J = 4.8 Hz, 1H), 6.53 (s, 1H), 4.18 (s, 2H), 4.09 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.0, 157.6, 157.3, 134.8, 134.5, 129.7, 127.1, 122.9, 119.1, 116.4, 116.2, 108.6, 60.3, 36.8, 13.7; HRMS (ESI) calcd for 315.0775 ([M+H]⁺), found 315.0779 ([M+H]⁺).

Ethyl 2-(5-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3g)



This compound was obtained in 83% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.68 (d, *J* = 4.8 Hz, 2H), 8.46 (d, *J* = 8.8 Hz, 1H), 7.35 (d, *J* = 0.8 Hz, 1H), 7.11 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.05 (t, *J* = 4.8 Hz, 1H), 6.52 (s, 1H), 4.18 (s, 2H), 4.09 (q, *J* = 7.2 Hz, 2H), 2.46 (s, 3H), 1.13 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.4, 157.8, 157.2, 134.7, 133.1, 131.0, 128.9, 124.3, 119.5, 115.9, 114.7, 109.1, 60.1, 36.9, 20.9, 13.7; HRMS (ESI) calcd for 295.1321 ([M+H]⁺), found 295.1326 ([M+H]⁺).

Ethyl 2-(5-methoxy-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3h)



This compound was obtained in 82% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.68 (d, *J* = 4.8 Hz, 2H), 8.54 (d, *J* = 9.2 Hz, 1H), 7.05 (dd, *J* = 4.8 and 3.6 Hz, 2H), 6.94 (dd, *J* = 9.2 and 2.8 Hz, 1H), 6.55 (s, 1H), 4.20 (s, 2H), 4.11 (t, *J* = 7.2 Hz, 2H), 3.89 (s, 3H), 1.16 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 170.8, 158.2, 157.7, 155.5, 134.2, 131.8, 129.9, 116.6, 116.3, 112.3, 109.7, 102.5, 60.6, 55.7, 37.4, 14.2. HRMS (ESI) calcd for 311.1270 ([M+H]⁺), found 311.1276 ([M+H]⁺).

Ethyl 2-(5-nitro-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3i)



This compound was obtained in 85% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.78 (d, J = 4.8 Hz, 2H), 8.61 (d, J = 9.2 Hz, 1H), 8.48 (d, J = 2.4 Hz, 1H), 8.17 (dd, J = 9.2, 2.4 Hz, 1H), 7.23 (t, J = 4.8 Hz, 1H), 6.74 (s, 1H), 4.23 (s, 2H), 4.09 (q, J = 7.2 Hz, 2H), 1.15 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 169.6, 157.6, 157.2, 142.7, 139.4, 136.5, 128.1, 118.1, 117.4, 116.1, 115.0, 109.7, 60.5, 36.5, 13.7; HRMS (ESI) calcd for 326.1015 ([M+H]⁺), found 326.1022 ([M+H]⁺).

Ethyl 2-(5-cyano-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3j)



This compound was obtained in 62% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.76 (d, J = 4.8 Hz, 2H), 8.61 (d, J = 8.8 Hz, 1H), 7.89 (d, J = 0.8 Hz, 1H), 7.52 (dd, J = 8.8, 2.0 Hz, 1H), 7.20 (t, J = 4.8 Hz, 1H), 6.65 (s, 1H), 4.22 (s, 2H), 4.08 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.2, 158.1, 157.8, 138.6, 136.1, 128.9, 126.4, 125.1, 120.3, 117.7,

116.2, 109.2, 105.2, 60.9, 36.9, 14.2; HRMS (ESI) calcd for 306.1117 ([M+H]⁺), found 306.1112 ([M+H]⁺).

Methyl 2-(2-ethoxy-2-oxoethyl)-1-(pyrimidin-2-yl)-1H-indole-5-carboxylate (3k)



This compound was obtained in 86% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.73 (d, *J* = 4.8 Hz, 2H), 8.55 (d, *J* = 8.8 Hz, 1H), 8.29 (d, *J* = 2.0 Hz, 1H), 7.98 (dd, *J* = 8.8, 2.0 Hz, 1H), 7.14 (t, *J* = 4.8 Hz, 1H), 6.66 (s, 1H), 4.20 (s, 2H), 4.07 (q, *J* = 7.2 Hz, 2H), 3.94 (s, 3H), 1.13 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.0, 167.3, 157.5, 157.4, 139.0, 134.5, 128.2, 124.2, 123.5, 122.1, 116.8, 114.5, 109.6, 60.3, 51.5, 36.6, 13.7; HRMS (ESI) calcd for 339.1219 ([M+H]⁺), found 339.1221 ([M+H]⁺).

Ethyl 2-(5-(benzylcarbamoyl)-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3l)



This compound was obtained in 83% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.73 (d, J = 4.8 Hz, 2H), 8.57 (d, J = 8.8 Hz, 1H), 8.04 (d, J = 1.2 Hz, 1H), 7.73 (dd, J = 8.8, 2.0 Hz, 1H), 7.42-7.29 (m, 5H), 7.14 (t, J = 4.8 Hz, 1H), 6.64 (s, 1H), 6.48 (t, J = 6.4 Hz, 1H), 4.70 (d, J = 6.4 Hz, 2H), 4.20 (s, 2H), 4.09 (q, J = 7.2 Hz, 2H), 1.12 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.0, 167.4, 157.6, 157.4, 138.2, 138.0, 134.6, 128.4, 128.3, 127.8, 127.5, 127.1, 121.7, 119.0, 116.7, 114.9, 109.5, 60.3, 43.7, 36.6, 12.7; HRMS (ESI) calcd for 414.1692 ([M+H]⁺), found 414.1695 ([M+H]⁺).

Ethyl 2-(6-fluoro-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3m)



This compound was obtained in 81% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.70 (d, J = 4.8 Hz, 2H), 8.37 (dd, J = 11.2, 2.0 Hz, 1H), 7.46 (dd, J = 4.8, 3.2 Hz, 1H), 7.09 (t, J = 4.8 Hz, 1H), 6.97 (dd, J = 8.8, 2.4 Hz, 1H), 6.56 (s, 1H), 4.18 (s, 2H), 4.09 (q, J = 7.2 Hz, 2H), 1.14 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.3, 160.5 (d, J = 236.0 Hz), 157.7, 157.3, 136.4 (d, J = 13.0 Hz), 133.5 (d, J = 3.9 Hz), 124.9, 120.1 (d, J = 9.9 Hz), 116.3, 109.9 (d, J = 24.1 Hz), 109.0, 102.4 (d, J = 28.9 Hz), 60.2, 36.8, 13.7; HRMS (ESI) calcd for 299.1070 ([M+H]⁺), found 299.1074 ([M+H]⁺).

Ethyl 2-(6-chloro-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3n)



This compound was obtained in 78% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.71 (d, J = 4.8 Hz, 2H), 8.64 (d, J = 2.0 Hz, 1H), 7.46 (d, J = 8.0 Hz, 1H), 7.19 (dd, J = 8.4, 2.0 Hz, 1H), 7.11 (t, J = 4.8 Hz, 1H), 6.56 (s, 1H), 4.18 (s, 2H), 4.08 (q, J = 7.2 Hz, 2H), 1.13 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.1, 157.5, 157.4, 136.7, 133.9, 128.7, 127.1, 122.2, 120.3, 116.5, 115.2, 109.0, 60.2, 36.7, 13.7; HRMS (ESI) calcd for 315.0775 ([M+H]⁺), found 315.0777 ([M+H]⁺).

Ethyl 2-(7-methyl-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (30)



This compound was obtained in 88% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.80 (d, J = 5.2 Hz, 2H), 7.46 (d, J = 7.6 Hz, 1H), 7.22 (t, J = 5.2 Hz, 1H), 7.12 (t, J = 7.6 Hz, 1H), 7.03 (d, J = 7.2 Hz, 1H), 6.60 (s, 1H), 4.01 (q, J = 7.2 Hz, 2H), 3.95 (s, 2H), 2.07 (s, 3H), 1.12 (t, J = 7.2 Hz, 3H); ¹³C

NMR (125MHz, CDCl₃) δ: 170.1, 158.3, 136.6, 133.9, 129.5, 126.0, 122.6, 121.8, 118.6, 118.3, 107.3, 60.9, 34.7, 20.9, 14.2; HRMS (ESI) calcd for 295.1321 ([M+H]⁺), found 295.1328 ([M+H]⁺).

Methyl 2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3p)



This compound was obtained in 83% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.73 (d, *J* = 4.8 Hz, 2H), 8.61 (d, *J* = 8.4 Hz, 1H), 7.59 (d, *J* = 7.6 Hz, 1H), 7.36-7.30 (m, 1H), 7.27-7.22 (m, 1H), 7.11 (t, *J* = 4.8 Hz, 1H), 6.63 (s, 1H), 4.21 (s, 2H), 3.65 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 171.3, 158.2, 157.8, 136.9, 133.4, 129.1, 123.4, 122.2, 120.2, 116.6, 115.4, 109.8, 51.9, 37.1; HRMS (ESI) calcd for 267.1008 ([M+H]⁺), found 267.1003 ([M+H]⁺).

Butyl 2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3q)



This compound was obtained in 86% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.70 (d, J = 4.8 Hz, 2H), 8.57 (d, J = 8.4 Hz, 1H), 7.56 (dd, J = 8.0, 0.8 Hz, 1H), 7.29 (dt, J = 7.2, 1.6 Hz, 1H), 7.22 (dt, J = 7.6, 1.2 Hz, 1H), 7.08 (t, J = 4.8 Hz, 1H), 6.59 (s, 1H), 4.21 (s, 2H), 4.02 (d, J = 6.8 Hz, 2H), 1.48 (m, 2H), 1.25 (m, 2H), 0.85 (t, J = 7.2 Hz, 3H); ¹³C NMR (125MHz, CDCl₃) δ : 170.9, 158.3, 157.8, 136.9, 133.6, 129.1, 123.4, 122.1, 120.1, 116.6, 115.4, 109.8, 64.6, 37.2, 30.6, 19.0, 13.7; HRMS (ESI) calcd for 309.1477 ([M+H]⁺), found 309.1479 ([M+H]⁺).

Isopropyl 2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3r)



This compound was obtained in 82% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.71 (d, *J* = 4.8 Hz, 2H), 8.56 (d, *J* = 8.4 Hz, 1H), 7.56 (dd, *J* = 7.6, 0.8 Hz, 1H), 7.29 (dt, *J* = 7.2, 1.2 Hz, 1H), 7.21 (dt, *J* = 7.2, 1.2 Hz, 1H), 7.09 (t, *J* = 4.8 Hz, 1H), 6.59 (s, 1H), 4.96 (m, 1H), 4.18 (s, 2H), 1.12 (d, *J* = 6.4 Hz, 6H); ¹³C NMR (125MHz, CDCl₃) δ : 169.8, 157.9, 157.3, 136.4, 133.2, 128.6, 122.8, 121.6, 119.6, 116.1, 114.9, 109.2, 67.4, 37.0, 21.3; HRMS (ESI) calcd for 295.1321 ([M+H]⁺), found 295.1329 ([M+H]⁺).

Tert-butyl 2-(1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3s)



This compound was obtained in 63% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.73 (d, J = 4.8 Hz, 2H), 8.53 (d, J = 8.4 Hz, 1H), 7.55 (dd, J = 7.6, 0.8 Hz, 1H), 7.27 (dt, J = 7.2, 1.2 Hz, 1H), 7.19 (dt, J = 7.2, 0.8 Hz, 1H), 7.09 (t, J = 4.8 Hz, 1H), 6.57 (s, 1H), 4.14 (s, 2H), 1.34 (s, 9H); ¹³C NMR (125MHz, CDCl₃) δ : 170.0, 158.4, 157.8, 136.9, 134.1, 129.1, 123.2, 122.0, 120.1, 116.5, 115.2, 109.4, 80.5, 38.2, 28.0; HRMS (ESI) calcd for 309.1477 ([M+H]⁺), found 309.1473 ([M+H]⁺).

Benzyl 2-(5-nitro-1-(pyrimidin-2-yl)-1H-indol-2-yl)acetate (3t)



This compound was obtained in 79% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.65 (d, J = 9.2 Hz, 1H), 8.50 (dd, J = 6.8, 3.6 Hz, 3H), 8.18 (dd, J = 9.2, 2.4 Hz, 1H), 7.40 – 7.28 (m, 5H), 7.06 (t, J = 4.8 Hz, 1H), 6.77 (s, 1H), 5.13 (s, 2H), 4.28 (s, 2H); ¹³C NMR (100 MHz, CDCl₃) δ : 169.9, 157.9, 157.5, 143.2, 139.8, 136.7, 135.8, 128.8, 128.6, 128.6, 128.3, 118.6, 117.7, 116.5, 115.6, 110.4, 66.6, 37.0; HRMS (ESI) calcd for 389.1250 ([M+H]⁺), found 389.1253 ([M+H]⁺).

Compound 3u



This compound was obtained in 81% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.70 (d, J = 4.8 Hz, 2H), 8.58 (d, J = 8.4 Hz, 0.15H), 7.57 (dd, J = 7.6, 1.2 Hz, 1H), 7.33-7.27 (m, 1H), 7.22 (t, J = 7.6 Hz, 1H), 7.08 (t, J = 4.8 Hz, 1H), 6.60 (s, 0.41H), 4.18 (m, 0.31H); ¹³C NMR (100 MHz, CDCl₃) δ : 171.3, 158.2, 157.8, 136.9, 136.8, 133.4, 133.3, 129.1, 129.0, 123.4, 123.3, 122.2, 120.2, 120.2, 116.6, 115.4, 115.2, 115.0, 109.8; HRMS (ESI): C₁₅H₆D₇N₃O₂ calcd for 275.1525 ([M+H]⁺), found 275.1531 ([M+H]⁺) 100%; C₁₅H₇D₆N₃O₂ calcd for 274.1463 ([M+H]⁺), found 274.1463 ([M+H]⁺) 88.0%; C₁₅H₈D₅N₃O₂ calcd for 273.1395 ([M+H]⁺), found 273.1400 ([M+H]⁺) 27.8%.

(E)-methyl 3-(2-(2-methoxy-2-oxoethyl)-1-(pyrimidin-2-yl)-1H-indol-7-yl)acrylate (4)



This compound was obtained in 68% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.70 (d, J = 4.8 Hz, 2H), 7.54 (dd, J = 7.6 and 0.8 Hz, 1H), 7.34 (d, J = 7.6 Hz, 1H), 7.26-7.17 (m, 2H), 7.13 (t, J = 7.6 Hz, 1H), 6.56 (s, 1H), 6.13 (d, J = 15.6 Hz, 1H), 3.93 (s, 2H), 3.61 (s, 3H), 3.46 (s, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 170.4, 167.4, 158.6, 158.3, 143.5, 135.2, 134.5, 130.1, 123.1, 122.5, 121.9, 120.7, 118.9, 116.4, 107.5, 52.1, 51.4, 34.6; HRMS (ESI) calcd for 351.1219 ([M+H]⁺), found 351.1225 ([M+H]⁺).

(E)-methyl 3-(2-(2-ethoxy-2-oxoethyl)-5-methyl-1-(pyrimidin-2-yl)-1H-indol-7-yl)acrylate (5)



This compound was obtained in 78% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.74 (d, *J* = 4.8 Hz, 2H), 7.40 (s, 1H), 7.33 (d, *J* = 15.6 Hz, 1H), 7.23 (t, *J* = 4.8 Hz, 2H), 6.54 (s, 1H), 6.19 (d, *J* = 15.6 Hz, 1H), 4.02-3.94 (m, 4H), 3.68 (s, 3H), 2.44 (s, 3H), 1.09 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 167.0, 167.4, 158.5, 158.4, 143.7, 134.8, 133.7, 131.2, 130.5, 124.3, 122.5, 120.3, 118.6, 116.1, 107.3, 60.9, 51.4, 34.9, 21.2, 14.1; HRMS (ESI) calcd for 379.1532 ([M+H]⁺), found 379.1536 ([M+H]⁺).

```
(E)-methyl 3-(2-(2-ethoxy-2-oxoethyl)-5-methoxy-1-(pyrimidin-2-yl)-1H-indol-7-yl)acrylate
```

(6)



This compound was obtained in 76% yield. ¹H NMR (400 MHz, CDCl₃) δ : 8.73 (d, *J* = 4.8 Hz, 2H), 7.32 (d, *J* = 15.6 Hz, 1H), 7.23 (t, *J* = 4.8 Hz, 1H), 7.10 (d, *J* = 2.4 Hz, 1H), 7.03 (d, *J* = 2.4 Hz, 1H), 6.55 (s, 1H), 6.19 (d, *J* = 15.6 Hz, 1H), 4.02-4.00 (m, 4H), 3.86 (s, 3H), 3.68 (s, 3H), 1.10 (t, *J* = 7.2 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃) δ : 167.0, 167.3, 158.5, 158.3, 155.2, 143.3, 135.5, 131.1, 130.5, 121.5, 118.6, 116.7, 111.5, 107.6, 105.3, 60.9, 55.9, 51.5, 35.0, 14.1; HRMS (ESI) calcd for 395.1481 ([M+H]⁺), found 395.1485 ([M+H]⁺).





This compound was obtained in 68% yield. ¹H NMR (400 MHz, DMSO- d_6) δ : 12.56 (s, 1H), 11.28 (s, 1H), 8.87 (t, J = 6.0 Hz, 1H), 8.11 (s, 1H), 7.65 (dd, J = 8.5, 1.6 Hz, 1H), 7.43 – 7.17 (m, 6H), 6.38 (s, 1H), 4.50 (d, J = 6.0 Hz, 2H), 3.78 (s, 2H); ¹³C NMR (100 MHz, DMSO- d_6) δ : 171.8, 167.8, 140.7, 138.2, 134.6, 128.7, 127.9, 127.7, 127.0, 125.7, 120.7, 119.8, 110.8, 102.0, 43.1, 34.1; HRMS (ESI) calcd for 309.1239 ([M+H]⁺), found 309.1245 ([M+H]⁺).

References

- S1 Y. Li, B.-J. Li, W.-H. Wang, W.-P. Huang, X.-S. Zhang, K. Chen and Z.-J. Shi, Angew. Chem. Int. Ed., 2011, 50, 2115.
- S2 L. Ackermann and A. V. Lygin, Org. Lett., 2011, 13, 3332.
- S3 J.-J. Shi, B. Zhou, Y.-X. Yang and Y.-C. Li, Org. Biomol. Chem., 2012, 10, 8953.
- S4 C.-D. Pan, H.-M. Jin, P. Xu, X. Liu, Y.-X. Cheng and C.-J. Zhu, *J. Org. Chem.*, 2013, **78**, 9494.
- S5 A. Bogdanova and V. V. Popik, J. Am. Chem. Soc., 2013, 125, 14153.



3a















3d





220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)

3e





 $\overleftarrow{}_{1,\,119}^{1,\,155}$





220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)











220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)



4.15 4.15 4.13 3.89 3.89

1.18 1.16 1.16





3h

8, 788 8, 768 8, 768 8, 768 8, 768 8, 768 8, 485 8, 485 8, 479 8, 171 8, 171 8, 171 8, 171 8, 171 8, 171 8, 174 $\overbrace{\substack{4,\ 101\\4,\ 101\\4,\ 065}}^{4,\ 123}$ $\in I_{1,129}^{1,165}$ $\overbrace{7, 224}{7, 224}$ 111 0.5 0.0 $-\frac{1.66.607}{157.248}$ - 60, 452 - 36, 467 - 13. 724

220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)

3j









3k

220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)

31



0.0

220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)





220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)



3n

220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)











220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 f1 (ppm)



3q $\begin{array}{c} 1.519\\ 1.519\\ 1.485\\ 1.447\\ 1.447\\ 1.447\\ 1.447\\ 1.447\\ 1.246\\ 1.246\\ 1.229\\ 1.229\\ 1.229\\ 1.229\\ 1.229\\ 1.229\\ 1.229\\ 1.229\\ 1.229\\ 1.223\\ 1.233\\ 1.$ $\chi^{8,\,709}_{8,\,561}$ 4, 205 4, 041 4, 007 7, 573 7, 571 7, 573 7, 553 7, 553 7, 250 7, 292 7, 215 7, 215 7, 216 7, 095 6, 953 7.5 7.0
 T
 T
 T

 5
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
 1
9.0 8.5 3. 29 F⁸⁰ ≈ 1.5 8.0 0.0 0.5 1.0 ▲ 18, 307 157, 739 157, 739 157, 739 157, 738 157, 738 157, 738 115, 115 115, 115 115, 115 - 170.915 - 37. 220 - 30. 585 - 19. 031 - 13. 684 ó 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 f1 (ppm) 0 -10 -20









220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 fl (ppm)



3t



3u





 $\zeta_{8.73}^{8.74}$ 7.03 7.03 7.725 7.725 7.725 7.725 7.725 7.725 7.725 7.725 7.725 7.725 4.02 4.00 4.00 13.86 13.86 ^{1,12}
 ^{1,12}
 ^{1,10}
 ^{1,10}
 ^{1,08} H₃C H₃C CH3 0.93 1.00 ± 1.04H 1.00-₹ 4.06 ± 3.10 ≠ 3.12 ± 1.96-1 3.09-1 0.0 9.5 5.5 5.0 4.5 f1 (ppm) 4.0 6.5 6.0 3.5 3.0 2.0 9.0 8.5 8.0 7.5 7.0 2.5 1.5 1.0 0.5 0. -14.13 -60.91 -55.93 -51.46 -35.01



6



110 90 80 70 60 50 40 f1 (ppm) 210 190 170 150 130 30 20 10 0 -10 -20

